Phase 4Not yet recruiting
FutureShape Family
FutureShape Family: A Randomised Controlled Trial of an Enhanced Family Care Intervention Targeting Intergenerational Obesity
- Sponsor
- Signe Torekov (Academic or other)
- Enrolment
- 400 planned
- Conditions
- Obesity; Overweight
- Interventions
- Family Care; Standard Care; Semaglutide (administered by PDS290 pen-injector); Placebo (administered by PDS290 pen-injector)
- Ages
- children, adults, older adults
- Registry
- NCT07872904
Full record on ClinicalTrials.gov
From the registry
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor mental health, and decreased life expectancy. Parental obesity is a strong predictor of intergenerational obesity and is closely associated with a child's body composition from childhood through to adulthood. Obesity pharmacotherapy effectively reduces body weight. In adults, we have shown that combining obesity pharmacotherapy with supervised exercise improves weight-loss maintenance compared with pharmacotherapy alone. Emerging evidence suggest that exercise may also limit weight regain after treatment cessation. Together with evidence linking physical activity, sleep, and eating behaviours to weight regulation, these findings support combining pharmacological treatment with interventions targeting multiple modifiable behaviours. Personalised, data-driven feedback may further facilitate sustained behavioural change, but few interventions have integrated…
Primary outcomes
- Change in body fat percentage
History
Study completion expected
Primary completion expected
Registered
Started